Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Disease
source: Internal Medicine
authors: Katahira M, Ogata Hsummary/abstract:
The recurrence rate associated with antithyroid drug (ATD) treatment for Graves’ disease (GD) is high compared with that for radioiodine therapy or surgery. It is important to identify patients in whom remission is unlikely, so that they are not given treatment that is destined to fail. The objective of this study was thus to evaluate factors influencing the prognosis of GD patients treated with ATDs.
One hundred and sixty-one patients were divided into two groups: 100 patients who could not discontinue ATDs for eight years or more (refractory group) and 61 patients who achieved remission within eight years after starting ATD treatment (nonrefractory group). The groups were compared in terms of age, thyroid function and thyroid-related autoantibodies at diagnosis, and the durations to the recovery of thyroid function and thyroid-related autoantibodies.
The baseline levels of free triiodothyronine (T3), free thyroxine (T4), thyroid-stimulating antibodies (TSAbs) and thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) were high, and the age at diagnosis and the baseline level of thyroglobulin autoantibodies (TgAbs) were low in the refractory group compared with those in the nonrefractory group. The durations to the recovery of TSH, free T4, TRAb and TSAb levels were longer in the refractory group than in the nonrefractory group. No significant difference was observed with regard to thyroid peroxidase autoantibodies.
We compared the clinical features of these two groups in order to identify factors influencing the prognosis of GD patients treated with ATDs. A low baseline level of TgAbs is associated with the refractoriness of GD to ATD treatment.
Which Factors Predict the Outcome of Radioactive Iodine Therapy of Graves’ Disease?Graves’ disease is the most common cau...
Remission of Graves’ Disease During Anti-Thyroid Drug Therapy: Time to Reconsider the Mechanism?Therapy of Graves' hyperthyroidism with ...
New Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
Graves’ Disease Treatment for Someone in Their 20sHyperthyroidism triggered by Graves’ d...
Radioactive Iodine Therapy vs. Antithyroid Medications for Graves’ DiseaseGraves disease is the most common cause ...
Optimal Iodine Supplementation During Antithyroid Drug Therapy for Graves’ Disease Is Associated With Lower Re...Objective: A relationship between iodin...
Cost-Utility Analysis Comparing Radioactive Iodine, Anti-Thyroid Drugs and Total Thyroidectomy for Primary Treatment...Objective: Little data is in existence ...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.